Andy Haigh is the President and CEO of Adapsyn Bioscience. He joined the company in 2017 after being instrumental in the company’s initial financing and collaboration. He was previously the second employee at Forbius Inc., a biologic drug developer acquired by BMS in 2020. Additionally, he spent five years at Lumira Capital, a leading Canadian venture capital firm, where he executed both equity and debt transactions in public and private companies developing novel therapeutics. He currently serves on the Board of Directors at BIOTECanada, Canada’s biotechnology industry association, and is the chair of the organization’s Emerging Company Advisory Board. Andy holds a PhD in Biology from Dalhousie University and an MBA from the Ivey Business School at Western University.

• 

  President in Adapsyn

  Making microbes work

• 

  Chief Executive Officer (CEO) in Adapsyn

  Making microbes work

• 

  Board of Director in Adapsyn

  Making microbes work